lobbying_activities: 4026968

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts. Sortable columns (indexed): client_name, issue_code, filing_year, filing_uuid. Sorting on any other column returns HTTP 400 (2026-09-04, #697) — use ?sql= with your own ORDER BY if you need it.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	is_no_activity	is_termination	received_date
4026968	58c29588-60ac-4f2a-a551-01a94d6f3fb4	Q2	LIFE SCIENCES PENNSYLVANIA	401105511	LIFE SCIENCES PENNSYLVANIA	2026	second_quarter	CPT	Strong intellectual property protections are the foundation for innovation in the life sciences. The U.S. patent system, though now ranked 12th worldwide by the U.S. Chamber of Commerce, maintains important protections for companies researching and developing new medicines and technologies. These protections are especially important for the many small life sciences companies that call Pennsylvania home, and for the technology transfer offices that many of our academic institutions operate to move inventions from the lab to widely available treatments and cures for patients. The University and Small Business Patent Procedures Act Of 1980, more commonly called the Bayh-Dole Act, provides recipients of federal research funding the right to retain ownership of the inventions that were conceived or first actually reduced to practice under their federal funding agreements. Intended to promote utilization of inventions arising from federally supported R&D and increase the number of inventions that progressed from the laboratories into the marketplace. Four decades on, changes to these policies would dramatically disrupt the already fragile ecosystem of academic research institutions, industry partners as well as private investment into treatments that have the potential to extend life expectancy in patients. This does not accurately account for the significant time and resources private investment organizations and companies make to research and develop safe, effective, and usable medicines. Life Sciences Pennsylvania and the academic research institutions as well as R&D based companies that call Pennsylvania home, understand the importance of the strong intellectual property protections that we have in the U.S. Exercising march-in rights will significantly disrupt an innovation ecosystem that already faces challenging odds developing novel therapies and technologies for unmet medical needs. Life Sciences Pennsylvania joins the Partnership for the U.S. Life Science Ecosystem (PULSE) in sharing the unique nature of mergers and acquisitions (M&A) within our membership. To successfully bring cutting edge breakthroughs from bench to bedside-from the earliest NIH funded research in the academic setting through large scale manufacturing, mergers and acquisitions are a cornerstone of the American success of innovation. DOJ and FTC regulatory changes should be nuanced in this space.	HOUSE OF REPRESENTATIVES,SENATE	0	0	2026-07-07T15:18:50-04:00